Scinai Immunotherapeutics Ltd. (SCNI) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
SCNI currently has 13.9B outstanding shares. with limited dilution risk as only 121M additional shares (0.9%) are authorized for issuance. The company has significantly diluted shareholders by 270.85% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 01, 2026 |
20-F filing | 13872.9M shares outstanding |
14B | 120M |
| May 12, 2025 |
POS AM filing: This POS AM filing relates to the offering of ADSs by a selling shareholder, including Commitment Shares and Advance Shares that may be sold to YA under a Purchase Agreement, with potential gross proceeds of up to $10.0 million for the company from sales of ADSs to YA as Advance Shares. |
4B | 120M |
| May 07, 2025 |
20-F filing | 3225.5M shares outstanding |
3.2B | 120M |
| Mar 04, 2025 |
F-1 filing: F-1 filing for an equity line offering of 3,022,796 ADSs by a selling shareholder. |
3.7B | 120M |
| May 15, 2024 |
20-F filing | 1857.2M shares outstanding |
1.9B | 120M |
| Jan 30, 2024 |
F-3 filing: This F-3 filing relates to the resale of up to 5,369,497 American Depositary Shares representing 2,147,798,800 Ordinary Shares by selling shareholders, issuable upon exercise of warrants. |
4.4M | 120M |
| Oct 30, 2023 |
F-1 filing: Resale of 1,215,345 American Depositary Shares representing 486,138,000 Ordinary Shares issuable upon exercise of warrants by selling shareholders. |
2.2B | 120M |
| Aug 18, 2023 |
F-3 filing: BiondVax Pharmaceuticals Ltd. may offer and sell to the public from time to time in one or more series or issuances up to $150,000,000 in the aggregate of American Depositary Shares, ordinary shares, warrants, subscription rights and/or units. |
1.3B | 110M |
| Jun 08, 2023 |
8-K filing: BiondVax Pharmaceuticals Ltd. entered into a License Agreement with Max-Planck-Innovation GmbH and the University Medical Center Gottingen to develop and commercialize VHH antibodies targeting Interleukin-17, issuing 17,000 American Depository Shares to the counterparties within 45 days of June 4, 2023. |
1.3B | 0 |
| May 15, 2023 |
10-Q filing | 1295.3M shares outstanding |
1.3B | 0 |
| Apr 17, 2023 |
10-K filing | 1313.6M shares outstanding |
1.3B | 0 |
| Sep 29, 2022 |
F-1 filing: The filing is an F-1 registration statement for an offering of American Depositary Shares (ADSs), each representing 40 ordinary shares, with an option for the underwriter to purchase additional ADSs. The ADSs are listed on the Nasdaq Capital Market under the symbol "BVXV." |
750M | 0 |
| Mar 28, 2022 |
20-F filing | 573.3M shares outstanding |
570M | 0 |
| May 13, 2021 |
20-F filing | 461.3M shares outstanding |
460M | 0 |
| Jul 29, 2020 |
F-3 filing: This F-3 filing outlines the potential distribution of securities, including common stock, through various methods such as block transactions, market sales, or negotiated prices, and describes the roles and potential liabilities of agents, underwriters, and dealers involved in the distribution process. |
450M | 0 |
| Jun 12, 2020 |
20-F filing | 454.1M shares outstanding |
450M | 0 |
| Jan 07, 2020 |
POS AM filing: This POS AM filing relates to ADSs issuable upon the exercise of Public Warrants and Underwriters Warrant in connection with the company's initial public offering. |
400M | 0 |